Acanthosis nigricans
☆ I le 2022 Stiftung Warentest i'uga mai Siamani, o le fa'amalieina o tagata fa'atau i ModelDerm sa na'o sina maualalo ifo nai lo fa'atalanoaga telemedicine totogi.
E taatele i tagata lapopoa.
References
Acanthosis nigricans o se fa'aaliga i le pa'u o se tulaga fa'avae. E masani ona aliali mai i gaugau pa'u e pei o le ua, tapuvae, ma le ga'o, e foliga mai e pei o ni pa'u lanu uliuli e le manino ona pito. Ole tulaga lea e masani ona feso'ota'i ile ma'i suka ma le inisalini tete'e, ae ise tulaga e seasea tupu, e mafai ona fa'asino ile kanesa ile tino. E ono alia'e fo'i ona o fa'afitauli o le homone po'o le inuina o vaila'au fa'apitoa e pei o vaila'au fa'ama'i ma fualaau fa'anatinati.
Acanthosis nigricans is a cutaneous manifestation of an underlying condition. It usually develops in skin folds, such as the back of the neck, axilla, and groin, where it presents as velvety hyper-pigmented patches with poorly defined borders. Acanthosis nigricans is most commonly associated with diabetes and insulin resistance, but rarely it can be a sign of internal malignancy. It can also occur with hormone disorders or with the use of certain medications like systemic glucocorticoids and oral contraceptives.
Acanthosis nigricans is a cutaneous manifestation of an underlying condition. It usually develops in skin folds, such as the back of the neck, axilla, and groin, where it presents as velvety hyper-pigmented patches with poorly defined borders. Acanthosis nigricans is most commonly associated with diabetes and insulin resistance, but rarely it can be a sign of internal malignancy. It can also occur with hormone disorders or with the use of certain medications like systemic glucocorticoids and oral contraceptives.
Acanthosis nigricans (AN) ose ma'i masani o le pa'u e feso'ota'i ma fa'afitauli fa'alesoifua maloloina e pei o le tete'e o le inisalini, ma'i suka, tino puta, ma'i kanesa, fa'afitauli o le hormonal, ma tali atu i vaila'au. O le togafitia o le AN e taula'i i le fa'atalanoaina o fa'afitauli fa'alesoifua maloloina. I le taimi muamua, e siaki e fomaʻi ni faailoga o le insulin resistance syndrome, lea e aofia ai le puta, maualuga cholesterol, toto maualuga, ma le maʻisuka ituaiga 2. E masani ona fa'atonu e foma'i le topical retinoids e fai ma filifiliga muamua o togafitiga, e mafai ona fesoasoani i le mafiafia o le pa'u. Ae ui i lea, atonu latou te le faʻatalanoaina atoatoa le faʻapogisaina o le paʻu. O isi togafitiga (salicylic acid, podophyllin, urea, calcipotriol) e manaʻomia foʻi le faʻaoga masani.
Acanthosis nigricans (AN) is a common dermatologic manifestation of systemic disease that is associated with insulin resistance, diabetes mellitus, obesity, internal malignancy, endocrine disorders, and drug reactions. Treatment of AN primarily focuses on resolution of the underlying disease processes causing the velvety, hyperpigmented, hyperkeratotic plaques found on the skin. Initial considerations for the AN workup include evaluating patients for insulin resistance syndrome characterized by obesity, dyslipidemia, hypertension, and diabetes mellitus type II. For cosmetic treatment, topical retinoids are considered the first-line therapy for insulin-resistant AN by modifying keratinization rate. However, topical tretinoin requires application for long durations and improves hyperkeratosis, but not hyperpigmentation. Topical salicylic acid, podophyllin, urea, and calcipotriol also require frequent application, while TCA peels may provide a faster and less time-intense burden.
Acanthosis nigricans (AN) is a common dermatologic manifestation of systemic disease that is associated with insulin resistance, diabetes mellitus, obesity, internal malignancy, endocrine disorders, and drug reactions. Treatment of AN primarily focuses on resolution of the underlying disease processes causing the velvety, hyperpigmented, hyperkeratotic plaques found on the skin. Initial considerations for the AN workup include evaluating patients for insulin resistance syndrome characterized by obesity, dyslipidemia, hypertension, and diabetes mellitus type II. For cosmetic treatment, topical retinoids are considered the first-line therapy for insulin-resistant AN by modifying keratinization rate. However, topical tretinoin requires application for long durations and improves hyperkeratosis, but not hyperpigmentation. Topical salicylic acid, podophyllin, urea, and calcipotriol also require frequent application, while TCA peels may provide a faster and less time-intense burden.
○ Mafuaaga
E masani ona tupu i tagata e laiti ifo i le 40 tausaga, atonu e maua mai i le kenera ma e feso'ota'i ma le puta po'o le endocrinopathies, e pei o le hypothyroidism, acromegaly, polycystic ovary disease, insulin-resistant diabetes po'o le Cushing's disease.
○ Togafitiga ― OTC Drugs
#40% urea cream